Venus Remedies
NSE: VENUSREM · Pharmaceuticals
Snapshot
Unlock Venus Remedies's vital signs
Growth · Profitability · Valuation · Strength · Conviction
Company Overview
Business
Venus Remedies Limited is a pharmaceutical company that develops and markets a diverse range of therapeutic products, including antibiotics, oncology treatments, and herbal formulations. The company operates both domestically in India and across international markets.
Business Model
The company generates revenue through the research, development, and sale of pharmaceutical products across various therapeutic segments, including antimicrobial resistance solutions and disinfectants.
Growth Outlook
Growth is driven by the company's focus on expanding its portfolio in specialized therapeutic areas and addressing the global challenge of antimicrobial resistance.
Key Risks
- Regulatory Compliance. The company faces stringent regulatory oversight from international health authorities, which could impact product approvals and market access.
- Competitive Pressure. The pharmaceutical sector is highly competitive, with constant pressure on pricing and the need for continuous investment in research and development.
- Supply Chain Vulnerability. Dependence on raw material imports and global logistics can expose the company to supply chain disruptions and price volatility.
- Intellectual Property Risk. The company's growth relies on its ability to protect its proprietary formulations and navigate the complex landscape of pharmaceutical patents.
Start your research today
Unlock AI insights, financials, peers and live data on Venus Remedies and 5,000+ companies — free.
Key Metrics
REVENUE
₹811 Cr
TTM · consolidated
NET PROFIT
₹116 Cr
TTM · consolidated
EPS
₹86.91
TTM · consolidated
RETURN ON EQUITY
19.0%
TTM · consolidated
RETURN ON CAPITAL EMPLOYED
23.9%
TTM · consolidated
P/E
19.5x
Q1 FY27 · consolidated
EV/EBITDA
12.6x
Q1 FY27 · consolidated
EBITDA MARGIN
21.9%
TTM · consolidated
NET PROFIT MARGIN
12.8%
Q1 FY27 · consolidated
DEBT TO EQUITY
0.0x
Q1 FY27 · consolidated
Peers · Pharmaceuticals
| Company | Mkt Cap | P/E | EV/EBITDA | Rev Gr YoY | EBITDA Mgn | ROE | ROCE | 1Y Return |
|---|---|---|---|---|---|---|---|---|
Venus RemediesVENUSREM | ₹2,265 Cr | 19.50 | 12.59 | 20.9% | 21.9% | 19.0% | 23.9% | +265.3% |
Windlas BiotechWINDLAS | ₹2,377 Cr | 35.61 | 19.64 | 18.5% | 13.0% | 12.2% | 16.8% | +14.5% |
Panacea BiotecPANACEABIO | ₹2,335 Cr | -328.66 | 130.32 | 10.3% | 2.6% | -1.1% | -0.4% | -6.4% |
Sai Parenterals LimitedSAIPARENT | ₹2,295 Cr | — | — | — | 10.0% | — | — | — |
Shukra Pharmaceuticals LimitedSHUKRAPHAR | ₹2,283 Cr | — | — | — | 51.0% | — | — | +83.1% |
Sakar HealthcareSAKAR | ₹2,256 Cr | 62.59 | 28.58 | 43.8% | 29.7% | 11.8% | 15.6% | +197.4% |
As of Q1 FY27
Financials
Venus Remedies
NSE: VENUSREM · Pharmaceuticals
Snapshot
Unlock Venus Remedies's vital signs
Growth · Profitability · Valuation · Strength · Conviction
Company Overview
Business
Venus Remedies Limited is a pharmaceutical company that develops and markets a diverse range of therapeutic products, including antibiotics, oncology treatments, and herbal formulations. The company operates both domestically in India and across international markets.
Business Model
The company generates revenue through the research, development, and sale of pharmaceutical products across various therapeutic segments, including antimicrobial resistance solutions and disinfectants.
Growth Outlook
Growth is driven by the company's focus on expanding its portfolio in specialized therapeutic areas and addressing the global challenge of antimicrobial resistance.
Key Risks
- Regulatory Compliance. The company faces stringent regulatory oversight from international health authorities, which could impact product approvals and market access.
- Competitive Pressure. The pharmaceutical sector is highly competitive, with constant pressure on pricing and the need for continuous investment in research and development.
- Supply Chain Vulnerability. Dependence on raw material imports and global logistics can expose the company to supply chain disruptions and price volatility.
- Intellectual Property Risk. The company's growth relies on its ability to protect its proprietary formulations and navigate the complex landscape of pharmaceutical patents.
Start your research today
Unlock AI insights, financials, peers and live data on Venus Remedies and 5,000+ companies — free.
Key Metrics
REVENUE
₹811 Cr
TTM · consolidated
NET PROFIT
₹116 Cr
TTM · consolidated
EPS
₹86.91
TTM · consolidated
RETURN ON EQUITY
19.0%
TTM · consolidated
RETURN ON CAPITAL EMPLOYED
23.9%
TTM · consolidated
P/E
19.5x
Q1 FY27 · consolidated
EV/EBITDA
12.6x
Q1 FY27 · consolidated
EBITDA MARGIN
21.9%
TTM · consolidated
NET PROFIT MARGIN
12.8%
Q1 FY27 · consolidated
DEBT TO EQUITY
0.0x
Q1 FY27 · consolidated
Peers · Pharmaceuticals
As of Q1 FY27